

PRESS RELEASE

Paris and Toulouse, January 6, 2015

**SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT
WITH ODDO CORPORATE FINANCE FOR THE 2ND SEMESTER OF 2014**

Pursuant to the liquidity contract granted to Oddo Corporate Finance regarding Genticel shares, the following resources were listed in the liquidity account as of December 31st, 2014, settlement date:

- 16,998 Genticel shares;
- 87,058.74 euros.

As of June 30, 2014, the most recent update, the following resources had been allocated to the liquidity account:

- 26,364 Genticel shares;
- 30,922.37 euros.

Upcoming events:

Oddo Forum - Lyon

January 8 - 9, 2015

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel is developing ProCervix, a first therapeutic vaccine in Phase II clinical trials, designed to eliminate cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

Genticel is based in Paris and Toulouse and was awarded "Prix Biotech d'Avenir 2014" in SW France category of the Deloitte Technology Fast 50 benchmark.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit www.genticel.com



CONTACT GENTICEL

Benedikt Timmerman
Chief Executive Officer
investors@genticel.com

INVESTOR CONTACT

Corinne Puissant
Tel.: +33 (0)1 53 67 36 77
cpuissant@actus.fr

PRESS CONTACT

Alexandra Prisa
Tel.: +33 (0)1 53 67 36 90
aprisa@actus.fr